18.79
-0.17 (-0.90%)
| Penutupan Terdahulu | 18.96 |
| Buka | 18.83 |
| Jumlah Dagangan | 957,909 |
| Purata Dagangan (3B) | 2,316,078 |
| Modal Pasaran | 3,470,317,056 |
| Harga / Pendapatan (P/E Ke hadapan) | 44.05 |
| Harga / Jualan (P/S) | 4.20 |
| Harga / Buku (P/B) | 3.79 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| Margin Keuntungan | -29.95% |
| Margin Operasi (TTM) | -25.97% |
| EPS Cair (TTM) | -1.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 107.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 35.65% |
| Nisbah Semasa (MRQ) | 5.20 |
| Aliran Tunai Operasi (OCF TTM) | -263.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -202.32 M |
| Pulangan Atas Aset (ROA TTM) | -8.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Legend Biotech Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 1.50 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 1.31% |
| % Dimiliki oleh Institusi | 47.92% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Westfield Capital Management Co Lp | 30 Sep 2025 | 6,094,486 |
| Hhlr Advisors, Ltd. | 30 Sep 2025 | 5,984,550 |
| Suvretta Capital Management, Llc | 30 Sep 2025 | 3,818,009 |
| Deerfield Management Company, L.P. | 30 Sep 2025 | 2,962,338 |
| Artisan Partners Limited Partnership | 30 Sep 2025 | 2,547,952 |
| Braidwell Lp | 30 Sep 2025 | 1,826,155 |
| Matthews International Capital Management Llc | 30 Sep 2025 | 1,028,447 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 90.00 (Barclays, 378.98%) | Beli |
| Median | 58.00 (208.68%) | |
| Rendah | 21.00 (TD Cowen, 11.76%) | Pegang |
| Purata | 59.25 (215.33%) | |
| Jumlah | 7 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 23.21 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Jan 2026 | 50.00 (166.10%) | Beli | 19.34 |
| TD Cowen | 22 Jan 2026 | 21.00 (11.76%) | Pegang | 19.34 |
| RBC Capital | 20 Jan 2026 | 66.00 (251.25%) | Beli | 23.42 |
| 13 Nov 2025 | 74.00 (293.83%) | Beli | 31.01 | |
| Oppenheimer | 07 Jan 2026 | 75.00 (299.15%) | Beli | 22.72 |
| Cantor Fitzgerald | 17 Dec 2025 | 74.00 (293.83%) | Beli | 21.42 |
| 13 Nov 2025 | 75.00 (299.15%) | Beli | 31.01 | |
| Morgan Stanley | 12 Dec 2025 | 50.00 (166.10%) | Beli | 22.32 |
| UBS | 08 Dec 2025 | 48.00 (155.46%) | Beli | 26.12 |
| Barclays | 13 Nov 2025 | 90.00 (378.98%) | Beli | 31.01 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |